Immunotherapy AXAL Tops Survival Mark in Cervical Cancer – OncLive
|
Immunotherapy AXAL Tops Survival Mark in Cervical Cancer
OncLive An immunotherapy targeting human papillomavirus (HPV)-infected cells led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer, according to a phase II study reported at the 2017 Society of Gynecology Oncology … HPV-Targeted Drug Sets Survival Mark in Cervical Cancer |
